The National Institute for Clinical Excellence (NICE) is being asked to develop technology appraisals on new treatments for breast cancer, rheumatoid arthritis, obesity, and crohn's disease as part of its 13th work programme. The NICE technology appraisal and clinical guideline work programmes are set by the Department of Health. Topics for referral include both new and emerging health technologies and those drugs, devices and procedures currently in use in the NHS where there is variation in practice. Topics are selected against published criteria.
(Media-Newswire.com) - The National Institute for Clinical Excellence ( NICE ) is being asked to develop technology appraisals on new treatments for breast cancer, rheumatoid arthritis, obesity, and crohn's disease as part of its 13th work programme.
The NICE technology appraisal and clinical guideline work programmes are set by the Department of Health. Topics for referral include both new and emerging health technologies and those drugs, devices and procedures currently in use in the NHS where there is variation in practice. Topics are selected against published criteria.
Andy Burnham, Health minister said:
"NICE's thirteenth work programme will provide valuable advice on issues important to the NHS. This latest referral contains our request that the Institute develop guidance on new treatments for breast cancer, lung cancer as well as guidance on new treatments for Crohn's disease.
"We are also asking NICE to produce guidance on the storage of donated Kidneys. Donated organs are a particularly precious resource and it is important to ensure that the NHS has the best possible information available on the most effective ways to store and preserve them.
"In addition we have asked NICE to produce guidance on a new drug for the treatment of obesity and overweight patients. This will add to the growing advice to the NHS and other agencies on obesity, following publication of NICE's clinical guideline this month."
The NHS is now required to make drugs available throughout England and Wales where NICE advises that they are clinically and cost effective.
Drawing on experts in each field and consulting widely with patient groups, NICE has produced guidance on 205 pharmaceuticals, 63 procedures, 17 diagnostics, five Health Promotion and 113 devices. The majority of NICE appraisals have suggested partial or full use of technologies.
NICE also develops clinical guidelines. This is broader guidance on best care for all aspects of the treatment of specific conditions. As part of the 13th wave work programme Ministers have also asked NICE to develop clinical guidelines on Rheumatoid arthritis in adults, Diarrhoea and vomiting in children and a Rapid Clinical Guideline on Acutely Ill Patients in Hospital. To date NICE has issued 41 guidelines on clinical areas such schizophrenia, multiple sclerosis, lung cancer, depression and fertility.
Notes for Editors
Technology Appraisals
NICE has been asked to produce guidance for the NHS on the following topics:
( a ) Single Technology Appraisals
Adalimumab for moderate to severely active crohn's disease To appraise the clinical and cost-effectiveness of adalimumab for moderate to severely active Crohn's disease.
Bevacizumab for non-small cell lung cancer
To appraise the clinical and cost-effectiveness of bevacizumab ( Avastin ) for non-small cell lung cancer.
Certolizumab pegol for rheumatoid arthritis
To appraise the clinical and cost-effectiveness of certolizumab pegol for rheumatoid arthritis.
Infliximab for ulcerative colitis
To appraise the clinical and cost effectiveness of infliximab for ulcerative colitis.
Lapatinib for advanced or metastatic breast cancer
To appraise the clinical and cost effectiveness of lapatinib plus capecitabine within its licensed indications for advanced, metastatic or recurrent breast cancer.
Rimonabant for the treatment of obese and overweight patients.
To appraise the clinical and cost effectiveness of rimonabant in its licensed indications as an adjunct to diet and exercise for the treatment of obese and overweight patients.
( b ) Multiple Technology Appraisals
Endovascular stents for abdominal aortic aneurysms To appraise the clinical and cost effectiveness of endovascular stent-grafts for repair of infrarenal abdominal aortic aneurysms.
Machine versus cold ( static ) storage of donated kidneys
To appraise the clinical and cost effectiveness of cold machine ( pulsatile ) perfusion systems and solutions for cold ( static ) storage for the preservation of donated kidneys.
Spinal cord stimulation for chronic pain
To appraise the clinical and cost effectiveness of spinal cord stimulation in the management of chronic pain of neuropathic or ischaemic origin.
Clinical Guidelines
These were referred to NICE in July 2006 and are included here for completeness.
Rheumatoid arthritis in adults
To prepare a clinical guideline on the management and treatment of RA in adults, including pharmacological ( drug sequencing ) and non pharmacological treatment and the timing of surgery.
Diarrhoea and vomiting in children
To prepare a clinical guideline on the assessment and management of acute diarrhoea and/or vomiting in children.
Rapid Clinical Guidelines
Rapid Clinical Guidelines are a new work stream within NICE's existing clinical guidelines programme. These guidelines will cover specific disease areas, rather than the use of specific medical technologies as covered by technology areas, but which also fall outside the usual broad scope that clinical guidelines cover. The first of these guidelines was referred to NICE in July 2006.
Acutely Ill Patients in Hospital
To prepare guidance on the care of acutely ill adults in hospital.
This story was released on 2007-02-08. Please make sure to visit the official company or organization web site to learn more about the original release date. See our disclaimer for additional information.
